Newborns can't see clearly at birth. In fact, vision is about 20/400, making the first days of sight very blurry, like a camera out of focus. But within a week, a baby can focus on objects about 8 to 12 inches from his face.
(Wellâ¦sort of ânew.â) Tresiba is a long-acting insulin (like Lantus or Levemir) made by NovoNordisk. Itâs been available in Europe for several years now and is still awaiting FDA approval in the USA. (UPDATE: Tresiba is now approved by the FDA for use in the USA!)
The company claims that UK patients with diabetes who started taking Tresiba (insulin degludec) after experiencing problems with Novo's own Levemir (insulin detemir) or Sanofi's Lantus (insulin glargine) reported reduced rates of the side effect hypoglycaemia, potentially reducing NHS costs.